Allergan (AGN) says Darpin data does not support Phase 3 trials.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
Go back to Allergan (AGN) says Darpin data does not support Phase 3 trials.
May 2, 2013 7:11 AM EDT
Lazard Capital upgraded Allergen (NYSE: AGN) from Hold to Buy.
For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.
Shares of Allergen closed at $98.67 yesterday, with a 52 week range of $81.28-$116.45.... More
May 1, 2013 2:31 PM EDT
Morgan Stanley downgraded Allergen (NYSE: AGN) from Overweight to Equalweight.
For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.
Shares of Allergen closed at $113.55 yesterday, with a 52 week range of $81.28-$116.45.... More
May 1, 2013 12:02 PM EDT
Analysts at RBC Capital think the market overreacted to news about Allergen's (NYSE: AGN) DARPin. Today Allergan's CEO said data on DARPin does not support Phase 3 trials, which will delay approval by 1-2 years. This sent shares lower by well over 10 percent, but RBC... More
May 1, 2013 11:06 AM EDT
Allergan, Inc. (NYSE: AGN) trading paused for volatility.... More
